TOKIWA-Bio

TOKIWA-Bio Inc. was founded in December 2014 based on an innovative discovery by The National Institute of Advanced Industrial Science and Technology (AIST). A company was authorized as one of "AIST Start-ups" in March 2015. A company specialize in R&D and practical application of gene-cell therapies, development of vectors of direct reprograming of cells for regenerative medicine, and biologics manufacture that can make the cost and process reduction. We are developing a pipeline of steals RNA vector (SRV)-based gene-cell therapies both internally and through multiple collaborations. We are advancing a broad pipeline of innovative gene therapies, initially focused on treatments for rare diseases, but through our collaborations and the strategic partnership we have to develop gene therapies for hemophilia and ischaemic disease, we have made the next step towards developing gene therapies targeting cancer and chronic diseases that affect larger populations. At present, we are engaged in development of device which can automatically establish iPS cells from blood monocyte and T-iPS cells from rare T cells in patients with cancer. It is our mission to provide patients, especially those suffering from diseases for which no effective therapy has been available to date, with innovative drugs as soon as possible in order to improve their Quality of Life (QOL).